Loss-of-Function Mutations in the Penicillin-Binding Protein PonA1 Confer Agar-Dependent Resistance to Durlobactam in Mycobacterium abscessus
Preprint
- 24 November 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Infections caused by the multidrug-resistant pathogen Mycobacterium abscessus (Mab) are notoriously difficult to treat. The novel β-lactamase inhibitor durlobactam, in combination with β-lactams, shows potent bactericidal activity against Mab, but the potential for acquired resistance remains a clinical concern. Objectives: To identify and characterize mechanisms of acquired resistance to durlobactam in Mab. Methods: In vitro single-step resistance selection was performed by plating wild-type Mab ATCC 19977 on agar containing durlobactam. Resistant mutants were isolated, and their genomes were sequenced. The resistance phenotype was confirmed by constructing a targeted gene deletion mutant and by transcriptional silencing using a CRISPR interference (CRISPRi) system. Minimum inhibitory concentrations (MICs) were determined by both, an agar-based method and broth microdilution. Results: Whole-genome sequencing of durlobactam-resistant mutants identified loss-of-function mutations in ponA1, a gene encoding a class A penicillin-binding protein involved in cell wall synthesis. Targeted deletion of ponA1 (ΔponA1) and CRISPRi-mediated knockdown of ponA1 expression both recapitulated the resistance phenotype, resulting in a significant increase in the durlobactam MIC on solid agar media. Strikingly, broth microdilution MICs remained largely unaffected. Conclusions: Inactivation of the peptidoglycan synthase PonA1 is a novel mechanism of resistance to durlobactam in Mab that is phenotypically expressed only during growth on solid surfaces. This finding identifies a specific genetic pathway for resistance and highlights that standard broth-based susceptibility testing could miss clinically relevant resistance mechanisms.Keywords
All Related Versions
- Version 1, 2025-11-24, Preprints
- Published version: Antibiotics, 15 (1), 7.
This publication has 21 references indexed in Scilit:
- The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus : From Laboratory Insights to Clinical Applications and the Case for Clinical TrialsClinical Infectious Diseases, 2025
- Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung DiseaseACS Infectious Diseases, 2025
- Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosisACS Infectious Diseases, 2024
- Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung diseaseNature Reviews Drug Discovery, 2024
- Characterization of Mycobacterium abscessus colony-biofilms based on bi-dimensional imagesAntimicrobial Agents and Chemotherapy, 2023
- CRISPR Inhibition of Essential Peptidoglycan Biosynthesis Genes in Mycobacterium abscessus and Its Impact on β-Lactam SusceptibilityAntimicrobial Agents and Chemotherapy, 2022
- Nontuberculous Mycobacterial Pulmonary Disease: Clinical Epidemiologic Features, Risk Factors, and DiagnosisChest, 2022
- CRISPR Interference (CRISPRi) for Targeted Gene Silencing in Mycobacteria2021
- “One-Two Punch”: Synergistic ß-Lactam Combinations forMycobacterium abscessusand Target Redundancy in the Inhibition of Peptidoglycan Synthesis EnzymesClinical Infectious Diseases, 2021
- Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lungJournal of Medical Microbiology, 2005